The evolution of lipid-lowering drugs in the management of cardiovascular risk: from the first cardiovascular risk reducing therapies to the novel challenging strategies
1. 系统已在2025-12-21 21:22:22对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/40945405/
其他信息:
D Henry, E Baugé, B Staels, F Lalloyer
Pharmacological Reviews, 2025
Elsevier
ABSTRACT Before the Framingham Heart Study, the concept of cardiovascular risk factors did not exist and cardiovascular diseases (CVD) were seen as a consequence of aging. The first two reports in 1957 and 1961 identified high cholesterol levels as a major risk factor for CVD, highlighting the importance of lipid management to reduce CVD risk. Since then, the growing knowledge of CVD pathophysiology led to the development of many drug classes to manage dyslipidemia and consequently cardiovascular risk. Unfortunately, many of them …
